Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 32Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 16Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Colorectal Neoplasms 11Sarcoma 9Lung Neoplasms 9Nasopharyngeal Carcinoma 7Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Head and Neck Neoplasms 5Glioma 5Esophageal Neoplasms 5Cholangiocarcinoma 5Recurrence 4Pancreatic Neoplasms 4Osteosarcoma 4Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Advanced Gastric Cancer 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Neoplasm Metastasis 3NSCLC 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Locally Advanced or Metastatic Gastric Adenocarcinoma × apatinib × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡